PE20221662A1 - Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos - Google Patents
Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismosInfo
- Publication number
- PE20221662A1 PE20221662A1 PE2022001140A PE2022001140A PE20221662A1 PE 20221662 A1 PE20221662 A1 PE 20221662A1 PE 2022001140 A PE2022001140 A PE 2022001140A PE 2022001140 A PE2022001140 A PE 2022001140A PE 20221662 A1 PE20221662 A1 PE 20221662A1
- Authority
- PE
- Peru
- Prior art keywords
- nitrogen
- methods
- based substituents
- compounds
- synthetic triterpenoids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950927P | 2019-12-19 | 2019-12-19 | |
| US201962950919P | 2019-12-19 | 2019-12-19 | |
| US202063198310P | 2020-10-09 | 2020-10-09 | |
| PCT/US2020/066073 WO2021127480A1 (en) | 2019-12-19 | 2020-12-18 | Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221662A1 true PE20221662A1 (es) | 2022-10-26 |
Family
ID=74554207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001140A PE20221662A1 (es) | 2019-12-19 | 2020-12-18 | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| BR112018005861B1 (pt) | 2015-09-23 | 2022-11-22 | Reata Pharmaceuticals, Inc | Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos |
| US20240293351A1 (en) * | 2020-12-11 | 2024-09-05 | Reata Pharmaceuticals Holdings, LLC | Methods of administering synthetic triterpenoids |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033288T2 (en) * | 2008-04-18 | 2017-11-28 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives |
| EP2279197B1 (en) * | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| RS58392B1 (sr) * | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| TWI649330B (zh) * | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| MX2021003643A (es) * | 2018-09-28 | 2021-08-19 | Sichuan Haisco Pharmaceutical Co Ltd | Derivados de terpenoides y usos de los mismos. |
-
2020
- 2020-12-18 BR BR112022011919A patent/BR112022011919A2/pt unknown
- 2020-12-18 TW TW109145170A patent/TWI889738B/zh active
- 2020-12-18 US US17/757,701 patent/US20230111914A1/en active Pending
- 2020-12-18 MX MX2022007595A patent/MX2022007595A/es unknown
- 2020-12-18 WO PCT/US2020/066073 patent/WO2021127480A1/en not_active Ceased
- 2020-12-18 KR KR1020227023129A patent/KR20220116209A/ko not_active Ceased
- 2020-12-18 PE PE2022001140A patent/PE20221662A1/es unknown
- 2020-12-18 JP JP2022537305A patent/JP2023507402A/ja active Pending
- 2020-12-18 PH PH1/2022/551493A patent/PH12022551493A1/en unknown
- 2020-12-18 AU AU2020405181A patent/AU2020405181A1/en not_active Abandoned
- 2020-12-18 IL IL293876A patent/IL293876B2/en unknown
- 2020-12-18 CR CR20220345A patent/CR20220345A/es unknown
- 2020-12-18 CA CA3159778A patent/CA3159778A1/en active Pending
- 2020-12-18 EP EP20851264.0A patent/EP4077347A1/en active Pending
- 2020-12-18 CN CN202080096545.0A patent/CN115087660A/zh active Pending
-
2022
- 2022-06-15 SA SA522432999A patent/SA522432999B1/ar unknown
- 2022-06-17 DO DO2022000127A patent/DOP2022000127A/es unknown
- 2022-06-17 CL CL2022001661A patent/CL2022001661A1/es unknown
- 2022-07-15 EC ECSENADI202255210A patent/ECSP22055210A/es unknown
- 2022-07-18 CO CONC2022/0010070A patent/CO2022010070A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020405181A1 (en) | 2022-07-14 |
| JP2023507402A (ja) | 2023-02-22 |
| KR20220116209A (ko) | 2022-08-22 |
| IL293876B2 (en) | 2026-03-01 |
| EP4077347A1 (en) | 2022-10-26 |
| CO2022010070A2 (es) | 2022-08-09 |
| US20230111914A1 (en) | 2023-04-13 |
| CN115087660A (zh) | 2022-09-20 |
| MX2022007595A (es) | 2022-07-19 |
| CL2022001661A1 (es) | 2023-01-27 |
| WO2021127480A1 (en) | 2021-06-24 |
| SA522432999B1 (ar) | 2025-04-10 |
| TWI889738B (zh) | 2025-07-11 |
| TW202135828A (zh) | 2021-10-01 |
| IL293876B1 (en) | 2025-11-01 |
| ECSP22055210A (es) | 2022-08-31 |
| BR112022011919A2 (pt) | 2022-09-06 |
| PH12022551493A1 (en) | 2023-11-13 |
| DOP2022000127A (es) | 2022-09-15 |
| CA3159778A1 (en) | 2021-06-24 |
| CR20220345A (es) | 2023-01-12 |
| IL293876A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004531A (es) | Compuestos de piridazinona y usos de los mismos. | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| CL2023003021A1 (es) | Moduladores de la proteólisis bcl6 y métodos de uso asociados, | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| PE20181067A1 (es) | Conjugados de anticuerpo-farmaco de pirrolobenzodiazepina y metodos de uso | |
| DOP2020000040A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| CR20200545A (es) | Inhibidores magl | |
| MX2020002825A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| MX2018012390A (es) | Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio. | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| CL2022001661A1 (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos | |
| CL2020002604A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. | |
| ECSP20013337A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| BR112018001469A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| DOP2017000188A (es) | Compuestos de benzoxaborol 4-sustituidos y uso de los mismos | |
| MX2021001441A (es) | Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso. | |
| PE20200727A1 (es) | Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso |